🚀 VC round data is live in beta, check it out!
BioArctic Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioArctic and similar public comparables like Tasly, Sinocelltech Group, Arcutis Biotherapeutics, Arcus Biosciences and more.
BioArctic Overview
About BioArctic
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
Founded
2003
HQ
Employees
107
Website
Sectors
Financials (LTM)
EV
$3B
BioArctic Financials
BioArctic reported last 12-month revenue of $196M and EBITDA of $105M.
In the same LTM period, BioArctic generated $189M in gross profit, $105M in EBITDA, and $88M in net income.
Revenue (LTM)
BioArctic P&L
In the most recent fiscal year, BioArctic reported revenue of $223M and EBITDA of $141M.
BioArctic expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $196M | XXX | $223M | XXX | XXX | XXX |
| Gross Profit | $189M | XXX | $211M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $105M | XXX | $141M | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 63% | XXX | XXX | XXX |
| EBIT Margin | 53% | XXX | 62% | XXX | XXX | XXX |
| Net Profit | $88M | XXX | $114M | XXX | XXX | XXX |
| Net Margin | 45% | XXX | 51% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioArctic Stock Performance
BioArctic has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
BioArctic's stock price is $34.97.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -2.8% | XXX | XXX | XXX | $1.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioArctic Valuation Multiples
BioArctic trades at 14.6x EV/Revenue multiple, and 27.4x EV/EBITDA.
EV / Revenue (LTM)
BioArctic Financial Valuation Multiples
As of April 18, 2026, BioArctic has market cap of $3B and EV of $3B.
Equity research analysts estimate BioArctic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioArctic has a P/E ratio of 35.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 14.6x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBITDA | 27.4x | XXX | 20.4x | XXX | XXX | XXX |
| EV/EBIT | 27.4x | XXX | 20.9x | XXX | XXX | XXX |
| EV/Gross Profit | 15.2x | XXX | 13.6x | XXX | XXX | XXX |
| P/E | 35.1x | XXX | 27.2x | XXX | XXX | XXX |
| EV/FCF | 19.1x | XXX | 12.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioArctic Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioArctic Margins & Growth Rates
BioArctic's revenue in the last 12 month declined by (23%).
BioArctic's revenue per employee in the last FY averaged $2.1M, while opex per employee averaged $0.7M for the same period.
BioArctic's rule of 40 is (19%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioArctic's rule of X is (77%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BioArctic Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (23%) | XXX | (40%) | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 63% | XXX | XXX | XXX |
| EBITDA Growth | (56%) | XXX | (81%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (19%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (77%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 25% | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioArctic Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioArctic | XXX | XXX | XXX | XXX | XXX | XXX |
| Tasly | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocelltech Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcutis Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcus Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Vera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioArctic M&A Activity
BioArctic acquired XXX companies to date.
Last acquisition by BioArctic was on XXXXXXXX, XXXXX. BioArctic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioArctic
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioArctic Investment Activity
BioArctic invested in XXX companies to date.
BioArctic made its latest investment on XXXXXXXX, XXXXX. BioArctic invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioArctic
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioArctic
| When was BioArctic founded? | BioArctic was founded in 2003. |
| Where is BioArctic headquartered? | BioArctic is headquartered in Sweden. |
| How many employees does BioArctic have? | As of today, BioArctic has over 107 employees. |
| Who is the CEO of BioArctic? | BioArctic's CEO is Gunilla Osswald. |
| Is BioArctic publicly listed? | Yes, BioArctic is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of BioArctic? | BioArctic trades under BIOA B ticker. |
| When did BioArctic go public? | BioArctic went public in 2017. |
| Who are competitors of BioArctic? | BioArctic main competitors are Tasly, Sinocelltech Group, Arcutis Biotherapeutics, Arcus Biosciences. |
| What is the current market cap of BioArctic? | BioArctic's current market cap is $3B. |
| What is the current revenue of BioArctic? | BioArctic's last 12 months revenue is $196M. |
| What is the current revenue growth of BioArctic? | BioArctic revenue growth (NTM/LTM) is (23%). |
| What is the current EV/Revenue multiple of BioArctic? | Current revenue multiple of BioArctic is 14.6x. |
| Is BioArctic profitable? | Yes, BioArctic is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioArctic? | BioArctic's last 12 months EBITDA is $105M. |
| What is BioArctic's EBITDA margin? | BioArctic's last 12 months EBITDA margin is 53%. |
| What is the current EV/EBITDA multiple of BioArctic? | Current EBITDA multiple of BioArctic is 27.4x. |
| What is the current FCF of BioArctic? | BioArctic's last 12 months FCF is $150M. |
| What is BioArctic's FCF margin? | BioArctic's last 12 months FCF margin is 76%. |
| What is the current EV/FCF multiple of BioArctic? | Current FCF multiple of BioArctic is 19.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.